The m6A demethylase ALKBH5 is highly expressed in various cancers, including AML, and promotes disease progression, but its specific role in modulating the PD-L1 axis and the immune microenvironment in AML remains unclear.<h4>Methods</h4>We analyzed the expression and prognostic significance of ALKBH5 in AML by integrating BloodSpot, GEO, and TCGA databases, and performed functional enrichment and immune infiltration analyses. Here, ALKBH5 is linked to cancer.